<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829305</url>
  </required_header>
  <id_info>
    <org_study_id>SHR2285-105</org_study_id>
    <nct_id>NCT04829305</nct_id>
  </id_info>
  <brief_title>A Trial of SHR2285 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Single Oral Administration in Healthy Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atridia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 open-label study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1 open-label study. The objective of this study is to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and pharmacodynamics of oral administered SHR2285 in healthy&#xD;
      subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Start of Treatment to end of study (approximately 7 days)</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-last</measure>
    <time_frame>Start of Treatment to outpatient (approximately 3 days)</time_frame>
    <description>Area under the concentration-time curve from time 0 to last time point after SHR2285 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-AUC0-inf</measure>
    <time_frame>Start of Treatment to outpatient (approximately 3 days)</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity after SHR2285 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Time to Cmax of SHR2285 and its metabolite SHR164471</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Maximum observed concentration of SHR2285 and its metabolite SHR164471</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-CL/F</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Apparent clearance of SHR2285 and its metabolite SHR164471</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Vz/F</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Apparent volume of distribution during terminal phase of SHR2285 and its metabolite SHR164471</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-t1/2</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Terminal elimination half-life of SHR2285 and its metabolite SHR164471</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation factor XI (FXI) activity</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Coagulation factor XI (FXI) activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of coagulation factor XI (FXI) activity thromboplastin time (APTT) and fold change from baseline</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Percentage change of coagulation factor XI (FXI) activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Activated partial thromboplastin time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold change of activated partial thromboplastin time from baseline</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Fold change of activated partial thromboplastin time from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Prothrombin time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold change of prothrombin time from baseline</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Fold change of prothrombin time from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International normalized ratio</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>International normalized ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold change of international normalized ratio from baseline</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Fold change of international normalized ratio from baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Low dose of SHR2285</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive a single dose of SHR2285 (low dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose of SHR2285</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive a single dose of SHR2285 (medium dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose of SHR2285</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive a single dose of SHR2285 (high dose).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2285</intervention_name>
    <description>SHR2285 is a selective inhibition of human FXIa small molecule compound.</description>
    <arm_group_label>High dose of SHR2285</arm_group_label>
    <arm_group_label>Low dose of SHR2285</arm_group_label>
    <arm_group_label>Medium dose of SHR2285</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand the trial procedures and possible adverse events, volunteers to&#xD;
             participate in the trial, and provides written informed consent.&#xD;
&#xD;
          -  Be able to comply with all the requirements and able to complete the study.&#xD;
&#xD;
          -  Male or female aged between 18 years and 55 years (inclusive) at the date of signed&#xD;
             consent form.&#xD;
&#xD;
          -  No clinically significant abnormalities in medical history, general physical&#xD;
             examination, vital signs, and laboratory tests.&#xD;
&#xD;
          -  Men and women of childbearing potential (WOCBP) must agree to take effective&#xD;
             contraceptive methods and have no plan to have a child from signing the consent form&#xD;
             to 16 weeks after IP administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any other investigational drugs or medical devices within 3 months prior to&#xD;
             screening (according to the date of signed consent form).&#xD;
&#xD;
          -  History of illicit or prescription drug abuse or addiction within one year of&#xD;
             screening, or positive urine drug screen at screening and Day-1. The urine drug screen&#xD;
             may be repeated at the discretion of the investigator and the reason for repeat needs&#xD;
             to be documented clearly (e.g., suspicion of false positive due to diet).&#xD;
&#xD;
          -  Receipt of any other investigational drugs or medical devices within 3 months prior to&#xD;
             screening (from the date of signed consent form).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Norton</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy You</last_name>
    <phone>+61192990433</phone>
    <email>kathyyou@atridia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Linear Clinical research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Jasmin Williams</last_name>
    </contact>
    <investigator>
      <last_name>2021-03-312 Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

